Sylvie Assadourian

Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma

Jaffer A. Ajani, M Fodor, Sergei Tjulandin et al. · Journal of Clinical Oncology · 2005 · 218 citations · Full text

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

Philippe Rougier, Hanno Riess, Robert Manges et al. · European Journal of Cancer · 2013 · 179 citations

Oncology, Pancreatic Cancer, Pharmacology +6

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

Xavier Pivot, P. Koralewski, Jorge Hidalgo et al. · Annals of Oncology · 2008 · 179 citations · Full text

Breast Oncology, Medicine, Pharmacology +5

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure

Jacques Bonneterre, Henri Roché, Alain Monnier et al. · British Journal of Cancer · 2002 · 130 citations · Full text

Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3)

Eric Van Cutsem, Roberto Labianca, D Hossfeld et al. · Journal of Clinical Oncology · 2005 · 130 citations

Gastroenterology, Pathology, Adjuvant Chemotherapy +17